Truist Financial Raises BeOne Medicines (NASDAQ:ONC) Price Target to $418.00

BeOne Medicines (NASDAQ:ONC) had its target price increased by equities research analysts at Truist Financial from $416.00 to $418.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price target would indicate a potential upside of 20.02% from the company’s current price.

ONC has been the subject of several other reports. Guggenheim increased their price objective on BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Thursday. Royal Bank Of Canada lifted their target price on BeOne Medicines from $436.00 to $451.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Morgan Stanley reissued an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a research report on Thursday, May 7th. Citizens Jmp increased their price target on shares of BeOne Medicines from $396.00 to $405.00 and gave the stock a “market outperform” rating in a research report on Thursday. Finally, Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $400.00.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $348.27 on Thursday. The company’s fifty day moving average is $296.52 and its two-hundred day moving average is $308.89. The company has a market cap of $38.21 billion, a P/E ratio of 61.32 and a beta of 0.49. BeOne Medicines has a 12-month low of $253.95 and a 12-month high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.40 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The business had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. Equities analysts expect that BeOne Medicines will post 6.26 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Xiaobin Wu sold 1,484 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $269.37, for a total transaction of $399,745.08. Following the completion of the sale, the chief operating officer directly owned 40 shares of the company’s stock, valued at $10,774.80. This trade represents a 97.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of the business’s stock in a transaction that occurred on Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95. Following the completion of the sale, the chief executive officer directly owned 8,122 shares of the company’s stock, valued at approximately $2,484,925.90. The trade was a 94.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 345,561 shares of company stock worth $105,625,947. Insiders own 6.19% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ONC. Generali Investments Management Co LLC bought a new position in shares of BeOne Medicines during the 2nd quarter valued at $2,280,000. Charles Schwab Trust Co bought a new stake in BeOne Medicines in the second quarter worth $855,000. Steadtrust LLC increased its position in BeOne Medicines by 3.7% during the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock worth $399,000 after buying an additional 50 shares during the last quarter. Empowered Funds LLC bought a new position in BeOne Medicines during the first quarter valued at about $201,000. Finally, Bank of America Corp DE raised its holdings in BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after buying an additional 26,441 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
• Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
• Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.